| Drug and Agent Index |
|
xxxv | |
| SECTION I General Principles of Pharmacology |
|
1 | (58) |
|
Chapter 1. Basic Principles of Pharmacology |
|
|
3 | (12) |
|
|
|
5 | (1) |
|
What Constitutes a Drug: Development and Approval of Therapeutic Agents |
|
|
5 | (4) |
|
|
|
6 | (1) |
|
Prescription Versus Over-the-Counter Medications |
|
|
7 | (1) |
|
|
|
8 | (1) |
|
Basic Concepts in Drug Therapy |
|
|
9 | (2) |
|
Dose-Response Curves and Maximal Efficacy |
|
|
9 | (1) |
|
|
|
10 | (1) |
|
|
|
11 | (4) |
|
Quantal Dose-Response Curves and the Median Effective Dose |
|
|
11 | (1) |
|
|
|
11 | (1) |
|
|
|
12 | (3) |
|
Chapter 2. Pharmacokinetics I: Drug Administration, Absorption, and Distribution |
|
|
15 | (17) |
|
|
|
15 | (5) |
|
|
|
15 | (2) |
|
|
|
17 | (3) |
|
Drug Absorption and Distribution: Bioavailability |
|
|
20 | (5) |
|
Membrane Structure and Function |
|
|
20 | (1) |
|
Movement Across Membrance Barriers |
|
|
21 | (4) |
|
Distribution of Drugs Within the Body |
|
|
25 | (1) |
|
Factors Affecting Distribution |
|
|
25 | (1) |
|
|
|
25 | (1) |
|
|
|
26 | (1) |
|
|
|
26 | (2) |
|
Adverse Consequences of Drug Storage |
|
|
28 | (1) |
|
Newer Techniques for Drug Delivery |
|
|
28 | (4) |
|
Controlled-Release Preparations |
|
|
28 | (1) |
|
Implanted Drug Delivery Systems |
|
|
28 | (1) |
|
Targeting Drug Delivery to Specific Cells and Tissues |
|
|
29 | (3) |
|
Chapter 3. Pharmacokinetics II: Drug Elimination |
|
|
32 | (12) |
|
|
|
32 | (3) |
|
Cellular Mechanisms of Drug Biotransformation |
|
|
33 | (1) |
|
Organs Responsible for Drug Biotransformation |
|
|
34 | (1) |
|
|
|
35 | (1) |
|
|
|
35 | (2) |
|
|
|
37 | (1) |
|
|
|
37 | (1) |
|
|
|
38 | (1) |
|
Dosing Schedules and Plasma-Concentration |
|
|
38 | (1) |
|
Variations in Drug Response and Metabolism |
|
|
39 | (5) |
|
Chapter 4. Drug Receptors |
|
|
44 | (15) |
|
Receptors Located on the Cell's Surface |
|
|
44 | (4) |
|
Surface Receptors Linked Directly to Ion Channels |
|
|
44 | (1) |
|
Surface Receptors Linked Directly to Enzymes |
|
|
45 | (1) |
|
Surface Receptors Linked Regulatory (G) Proteins: Role of the Second Messenger |
|
|
46 | (2) |
|
|
|
48 | (1) |
|
Drug-Receptor Interactions |
|
|
48 | (1) |
|
Functional Aspects of Drug-Receptor Interactions |
|
|
49 | (4) |
|
|
|
50 | (1) |
|
|
|
50 | (1) |
|
Classification of Drugs: Agonist Versus Antagonist |
|
|
51 | (1) |
|
Competitive Versus Noncompetitive Antagonists |
|
|
52 | (1) |
|
|
|
52 | (1) |
|
|
|
53 | (1) |
|
Receptor Desensitization and Down-Regulation |
|
|
53 | (1) |
|
|
|
54 | (1) |
|
Nonreceptor Drug Mechanisms |
|
|
54 | (5) |
| SECTION II Pharmacology of the Central Nervous System |
|
59 | (100) |
|
Chapter 5. Central Nervous System Pharmacology: General Principles |
|
|
61 | (10) |
|
|
|
61 | (3) |
|
|
|
61 | (1) |
|
|
|
62 | (1) |
|
|
|
63 | (1) |
|
Mesencephalom and Brainstem |
|
|
63 | (1) |
|
|
|
63 | (1) |
|
|
|
64 | (1) |
|
|
|
64 | (1) |
|
|
|
64 | (1) |
|
|
|
65 | (2) |
|
|
|
66 | (1) |
|
|
|
66 | (1) |
|
|
|
66 | (1) |
|
|
|
67 | (1) |
|
|
|
67 | (1) |
|
CNS Drugs: General Mechanisms |
|
|
67 | (4) |
|
Chapter 6. Sedative-Hypnotic and Antianxiety Agents |
|
|
71 | (12) |
|
|
|
71 | (3) |
|
|
|
74 | (1) |
|
|
|
74 | (2) |
|
|
|
74 | (1) |
|
|
|
75 | (1) |
|
|
|
76 | (1) |
|
Problems and Adverse Effects |
|
|
76 | (1) |
|
Tolerance and Physical Dependence |
|
|
76 | (1) |
|
|
|
76 | (1) |
|
|
|
77 | (1) |
|
|
|
77 | (2) |
|
|
|
77 | (1) |
|
Nonbenzodiazepine Antianxiety Drugs |
|
|
78 | (1) |
|
Problems and Adverse Effects |
|
|
79 | (1) |
|
Special Consideration of Sedative-Hypnotic and Antianxiety Agents in Rehabilitation |
|
|
79 | (1) |
|
|
|
80 | (3) |
|
|
|
80 | (3) |
|
Chapter 7. Drugs Used to Treat Affective Disorders: Depression and Manic-Depression |
|
|
83 | (13) |
|
|
|
83 | (8) |
|
|
|
83 | (1) |
|
Pathophysiology of Depression |
|
|
84 | (2) |
|
|
|
86 | (3) |
|
|
|
89 | (1) |
|
Problems and Adverse Effects |
|
|
89 | (1) |
|
Use of Antidepressants in Chronic Pain |
|
|
90 | (1) |
|
Treatment of Manic-Depression: Antimanic Drugs |
|
|
91 | (1) |
|
|
|
91 | (1) |
|
|
|
91 | (1) |
|
Absorption and Distribution |
|
|
92 | (1) |
|
Problems and Adverse Effects of Lithium |
|
|
92 | (1) |
|
Special Concerns in Rehabilitation Patients |
|
|
92 | (2) |
|
|
|
94 | (2) |
|
|
|
94 | (2) |
|
Chapter 8. Antipsychotic Drugs |
|
|
96 | (11) |
|
|
|
96 | (1) |
|
Neurotransmitter Changes in Schizophrenia |
|
|
97 | (1) |
|
Antipsychotic Classes and Mechanisms of Action |
|
|
97 | (3) |
|
|
|
100 | (1) |
|
Other Uses of Antipsychotics |
|
|
100 | (1) |
|
Problems and Adverse Effects |
|
|
100 | (3) |
|
|
|
100 | (3) |
|
|
|
103 | (1) |
|
|
|
103 | (1) |
|
|
|
103 | (1) |
|
|
|
103 | (1) |
|
Special Concerns in Rehabilitation Patients |
|
|
104 | (1) |
|
|
|
104 | (3) |
|
|
|
104 | (3) |
|
Chapter 9. Antiepileptic Drugs |
|
|
107 | (12) |
|
Classification of Epileptic Seizures |
|
|
108 | (1) |
|
Rationale for Drug Treatment |
|
|
109 | (1) |
|
Drugs Used to Treat Epilepsy |
|
|
109 | (4) |
|
|
|
109 | (1) |
|
|
|
110 | (1) |
|
|
|
111 | (1) |
|
|
|
111 | (1) |
|
|
|
111 | (1) |
|
|
|
112 | (1) |
|
|
|
112 | (1) |
|
|
|
112 | (1) |
|
Selection of Specific Antiepileptic Agent |
|
|
113 | (1) |
|
Single-Drug Therapy in Epilepsy |
|
|
113 | (1) |
|
|
|
114 | (1) |
|
Special Precautions During Pregnancy |
|
|
114 | (1) |
|
Treatment of Status Epilepticus |
|
|
115 | (1) |
|
Special Concerns in Rehabilitation Patients |
|
|
115 | (1) |
|
|
|
116 | (3) |
|
|
|
116 | (3) |
|
Chapter 10. Pharmacologic Management of Parkinson's Disease |
|
|
119 | (16) |
|
Pathophysiology of Parkinson's Disease |
|
|
120 | (1) |
|
Etiology of Parkinson's Disease: Potential Role of Toxic Substances |
|
|
120 | (2) |
|
Therapeutic Agents in Parkinsonism |
|
|
122 | (8) |
|
|
|
122 | (6) |
|
Other Drugs Used to Treat Parkinson's Disease |
|
|
128 | (2) |
|
Clinical Course of Parkinson's Disease: When to Use Specific Drugs |
|
|
130 | (1) |
|
Tissue Transplants in Parkinson's Disease |
|
|
130 | (1) |
|
Special Considerations for Rehabilitation |
|
|
131 | (1) |
|
|
|
132 | (3) |
|
|
|
132 | (3) |
|
Chapter 11. General Anesthetics |
|
|
135 | (12) |
|
General Anesthesia: Requirements |
|
|
135 | (1) |
|
Stages of General Anesthesia |
|
|
136 | (1) |
|
General Anesthetic Agents: Classification and Use According to Routes of Administration |
|
|
136 | (1) |
|
General Anesthetics: Specific Agents |
|
|
137 | (2) |
|
|
|
137 | (2) |
|
|
|
139 | (1) |
|
|
|
139 | (1) |
|
|
|
140 | (2) |
|
Actions of Inhaled Anesthetics |
|
|
140 | (2) |
|
Actions of Intravenous Anesthetics |
|
|
142 | (1) |
|
Adjuvants in General Anesthesia |
|
|
142 | (2) |
|
|
|
142 | (1) |
|
|
|
142 | (2) |
|
Special Concerns in Rehabilitation |
|
|
144 | (1) |
|
|
|
145 | (2) |
|
|
|
145 | (2) |
|
Chapter 12. Local Anesthetics |
|
|
147 | (12) |
|
Types of Local Anesthetics |
|
|
148 | (1) |
|
|
|
149 | (1) |
|
Clinical Use of Local Anesthetics |
|
|
150 | (2) |
|
|
|
152 | (1) |
|
|
|
153 | (1) |
|
Systemic Effects of Local Anesthetics |
|
|
154 | (1) |
|
Significance in Rehabilitation |
|
|
155 | (1) |
|
|
|
156 | (3) |
|
|
|
156 | (3) |
| SECTION III Drugs Affecting Skeletal Muscle |
|
159 | (16) |
|
Chapter 13. Skeletal Muscle Relaxants |
|
|
161 | (14) |
|
Increased Muscle Tone: Spasticity Versus Muscle Spasms |
|
|
161 | (2) |
|
Specific Agents Used to Produce Skeletal Muscle Relaxation |
|
|
163 | (1) |
|
|
|
163 | (4) |
|
|
|
163 | (1) |
|
|
|
164 | (1) |
|
|
|
165 | (1) |
|
|
|
166 | (1) |
|
|
|
167 | (1) |
|
|
|
167 | (1) |
|
|
|
168 | (1) |
|
|
|
168 | (1) |
|
|
|
168 | (1) |
|
|
|
168 | (1) |
|
|
|
169 | (1) |
|
Treatment of Muscle Spasms |
|
|
169 | (1) |
|
Special Concerns in Rehabilitation Patients |
|
|
170 | (1) |
|
|
|
171 | (4) |
|
|
|
171 | (4) |
| SECTION IV Drugs Used to Treat Pain and Inflammation |
|
175 | (70) |
|
Chapter 14. Opioid Analgesics |
|
|
177 | (17) |
|
Source of Opioid Analgesics |
|
|
177 | (1) |
|
Endogenous Opioid Peptides and Opioid Receptors |
|
|
178 | (2) |
|
|
|
178 | (1) |
|
|
|
179 | (1) |
|
Classification of Specific Agents |
|
|
180 | (2) |
|
|
|
182 | (1) |
|
|
|
183 | (3) |
|
Effect of Narcotic Analgesics on the Spinal Cord |
|
|
183 | (1) |
|
Effect of Narcotic Analgesics on the Brain |
|
|
184 | (1) |
|
Peripheral Effects of Opioids |
|
|
184 | (2) |
|
|
|
186 | (1) |
|
|
|
186 | (1) |
|
Use of Opioids in Patient-Controlled Analgesia |
|
|
187 | (1) |
|
|
|
187 | (1) |
|
Problems and Adverse Effects |
|
|
187 | (1) |
|
Concepts of Addiction, Tolerance, and Physical Dependence |
|
|
188 | (2) |
|
|
|
188 | (1) |
|
|
|
188 | (1) |
|
Tolerance and Dependence During Therapeutic Opioid Use |
|
|
189 | (1) |
|
Use of Methadone to Treat Opioid Addiction |
|
|
190 | (1) |
|
Special Concerns in Rehabilitation Patients |
|
|
190 | (1) |
|
|
|
190 | (4) |
|
|
|
190 | (4) |
|
Chapter 15. Nonsteroidal Anti-Inflammatory Drugs |
|
|
194 | (19) |
|
Aspirin and Other NSAIDs: General Aspects |
|
|
194 | (1) |
|
Prostaglanding, Thormboxanes, and Leukotrienes |
|
|
195 | (4) |
|
|
|
195 | (2) |
|
Role of Eicosanoids in Health and Disease |
|
|
197 | (2) |
|
Mechanism of NSAID Action: Inhibition of Prostaglandin and Thromboxane Synthesis |
|
|
199 | (1) |
|
Aspirin: Prototypical NSAID |
|
|
199 | (1) |
|
Clinical Applications of Aspirin-Like Drugs |
|
|
200 | (1) |
|
Treatment of Pain and Inflammation |
|
|
200 | (1) |
|
|
|
200 | (1) |
|
Treatment of Vascular Disorders |
|
|
200 | (1) |
|
|
|
201 | (1) |
|
Problems and Adverse Effects of Aspirin-Like Drugs |
|
|
201 | (2) |
|
Gastrointestinal Problems |
|
|
201 | (1) |
|
|
|
202 | (1) |
|
Comparision of Aspirin to Other NSAIDs |
|
|
203 | (4) |
|
|
|
207 | (1) |
|
Pharmacokinetics of NSAIDs and Acetaminophen |
|
|
207 | (1) |
|
Special Concerns in Rehabilitation Patients |
|
|
208 | (1) |
|
|
|
208 | (5) |
|
Nonsteroidal Anti-Inflammatory Drugs |
|
|
208 | (5) |
|
Chapter 16. Pharmacologic Management of Pheumatoid Arthritis and Osteoarthritis |
|
|
213 | (19) |
|
|
|
213 | (11) |
|
Immune Basis for Rheumatoid Arthritis |
|
|
214 | (1) |
|
Overview of Drug Therapy in Rheumatoid Arthritis |
|
|
215 | (1) |
|
Nonsteroidal Anti-Inflammatory Drugs |
|
|
216 | (1) |
|
|
|
217 | (1) |
|
Disease-Modifying Antirheumatic Drugs |
|
|
218 | (5) |
|
DMARD Combinations Used in Rheumatoid Arthritis |
|
|
223 | (1) |
|
Newer and Nontraditional Therapies for Rheumatoid Arthritis |
|
|
224 | (1) |
|
|
|
224 | (3) |
|
|
|
225 | (1) |
|
|
|
225 | (1) |
|
Special Concerns for Antiarthritic Drug Therapy in Rehabilitation Patients |
|
|
226 | (1) |
|
|
|
227 | (5) |
|
|
|
227 | (5) |
|
Chapter 17. Patient-Controlled Analgesia |
|
|
232 | (13) |
|
Pharmacokinetic Basis for PCA |
|
|
232 | (2) |
|
PCA Dosing Strategies and Parameters |
|
|
234 | (1) |
|
Types of Analgesics Used for PCA |
|
|
235 | (1) |
|
Administration Routes During PCA |
|
|
235 | (5) |
|
|
|
235 | (1) |
|
Epidural and Intrathecal PCA |
|
|
236 | (2) |
|
|
|
238 | (2) |
|
Comparision of PCA to Traditional Methods of Analgesic Administration |
|
|
240 | (2) |
|
Problems and Side Effects of PCA |
|
|
241 | (1) |
|
Pharmacologic Side Effects |
|
|
241 | (1) |
|
Problems with PCA Delivery |
|
|
242 | (1) |
|
Special Concerns for PCA in Rehabilitation Patients |
|
|
242 | (1) |
|
|
|
243 | (2) |
|
Patient-Controlled Analgesia |
|
|
243 | (2) |
| SECTION V Autonomic and Cardiovascular Pharmacology |
|
245 | (122) |
|
Chapter 18. Introduction to Autonomic Pharmacology |
|
|
247 | (12) |
|
Anatomy of the Autonomic Nervous System: Sympathetic and Parasympathetic Divisions |
|
|
247 | (2) |
|
Preganglionic and Postganglionic Neurons |
|
|
248 | (1) |
|
|
|
248 | (1) |
|
Parasympathetic Organization |
|
|
248 | (1) |
|
Functional Aspects of the Sympathetic and Parasympathetic Divisions |
|
|
249 | (1) |
|
Function of the Adrenal Medulla |
|
|
250 | (1) |
|
Autonomic Integration and Control |
|
|
251 | (1) |
|
Autonomic Neurotransmitters |
|
|
252 | (1) |
|
Acetylcholine and Norepinephrine |
|
|
252 | (1) |
|
Other Autonomic Neurotransmitters |
|
|
253 | (1) |
|
|
|
253 | (3) |
|
|
|
253 | (1) |
|
|
|
254 | (2) |
|
Pharmacologic Significance of Autonomic Receptors |
|
|
256 | (3) |
|
Chapter 19. Cholinergic Drugs |
|
|
259 | (12) |
|
|
|
259 | (1) |
|
|
|
260 | (5) |
|
Direct-Acting Cholinergic Stimulants |
|
|
260 | (2) |
|
Indirect-Acting Cholinergic Stimulants |
|
|
262 | (1) |
|
Clinical Applications of Cholinergic Stimulants |
|
|
263 | (1) |
|
Adverse Effects of Cholinergic Stimulants |
|
|
264 | (1) |
|
|
|
265 | (6) |
|
Source and Mechanism of Action of Antimuscarinic Anticholinergic Drugs |
|
|
265 | (1) |
|
Clinical Applications of Antimuscarinic Drugs |
|
|
266 | (3) |
|
Side Effects of Anticholinergic Drugs |
|
|
269 | (2) |
|
Chapter 20. Adrenergic Drugs |
|
|
271 | (17) |
|
Adrenergic Receptors Subclassification |
|
|
272 | (1) |
|
|
|
273 | (6) |
|
|
|
273 | (2) |
|
|
|
275 | (2) |
|
Drugs with Mixed Alpha and Beta Agonist Activity |
|
|
277 | (2) |
|
|
|
279 | (9) |
|
|
|
279 | (2) |
|
|
|
281 | (3) |
|
Other Drugs That Inhibit Adrenergic Neurons |
|
|
284 | (4) |
|
Chapter 21. Antihypertensive Drugs |
|
|
288 | (21) |
|
Normal Control of Blood Pressure |
|
|
289 | (1) |
|
Pathogenesis of Hypertension |
|
|
290 | (1) |
|
Essential Versus Secondary Hypertension |
|
|
290 | (1) |
|
Possible Mechanisms in Essential Hypertension |
|
|
290 | (1) |
|
|
|
291 | (1) |
|
|
|
291 | (3) |
|
Mechanism of Action and Rationale for Use |
|
|
291 | (2) |
|
Classification of Diuretics |
|
|
293 | (1) |
|
Adverse Effects of Diuretics |
|
|
294 | (1) |
|
|
|
294 | (5) |
|
|
|
295 | (1) |
|
|
|
296 | (1) |
|
Presynaptic Adrenergic Inhibitors |
|
|
297 | (1) |
|
|
|
298 | (1) |
|
|
|
298 | (1) |
|
|
|
299 | (1) |
|
Mechanism of Action and Rationale for Use |
|
|
299 | (1) |
|
|
|
299 | (1) |
|
|
|
300 | (1) |
|
Angiotensin-Converting Enzyme Inhibitors |
|
|
300 | (2) |
|
Mechanism of Action and Rationale for Use |
|
|
300 | (1) |
|
|
|
301 | (1) |
|
|
|
301 | (1) |
|
|
|
302 | (1) |
|
|
|
302 | (1) |
|
|
|
302 | (1) |
|
Stepped-Care Approach to Hypertension |
|
|
302 | (1) |
|
Nonpharmacologic Treatment of Hypertension |
|
|
303 | (1) |
|
Special Concerns in Rehabilitation Patients |
|
|
303 | (1) |
|
|
|
304 | (5) |
|
|
|
304 | (5) |
|
Chapter 22. Treatment of Angina Pectoris |
|
|
309 | (14) |
|
Drugs Used to Treat Angina Pectoris |
|
|
310 | (1) |
|
|
|
310 | (2) |
|
Mechanism of Action and Rationale for Use |
|
|
310 | (1) |
|
|
|
311 | (2) |
|
Adverse Side Effects of Nitrates |
|
|
313 | (1) |
|
|
|
313 | (1) |
|
Mechanism of Action and Rationale for Use |
|
|
313 | (1) |
|
|
|
313 | (1) |
|
|
|
314 | (1) |
|
|
|
314 | (2) |
|
Mechanism of Action and Rationale for Use |
|
|
314 | (1) |
|
|
|
315 | (1) |
|
|
|
315 | (1) |
|
Treatment of Specific Types of Angina Pectoris |
|
|
316 | (2) |
|
|
|
316 | (1) |
|
Variant Angina (Prinzmetal's Ischemia) |
|
|
317 | (1) |
|
|
|
317 | (1) |
|
Nonpharmacological Management of Angina Pectoris |
|
|
318 | (1) |
|
Special Concerns in Rehabilitation Patients |
|
|
318 | (1) |
|
|
|
319 | (4) |
|
|
|
319 | (4) |
|
Chapter 23. Treatment of Cardiac Arrhythmias |
|
|
323 | (12) |
|
Cardiac Electrophysiology |
|
|
323 | (2) |
|
Cardiac Action Potentials |
|
|
323 | (2) |
|
|
|
325 | (1) |
|
Normal Conduction of the Cardiac Action Potential |
|
|
325 | (1) |
|
Mechanisms of Cardiac Arrhythmias |
|
|
325 | (1) |
|
|
|
326 | (1) |
|
Classification of Antiarrhythmic Drugs |
|
|
327 | (1) |
|
Class I: Sodium Channel Blockers |
|
|
327 | (2) |
|
Mechanism of Action and Rationale for Use |
|
|
327 | (2) |
|
|
|
329 | (1) |
|
|
|
329 | (1) |
|
|
|
329 | (1) |
|
Mechanism of Action and Rationale for Use |
|
|
329 | (1) |
|
|
|
330 | (1) |
|
|
|
330 | (1) |
|
Class III: Drugs That Prolong Repolarization |
|
|
330 | (1) |
|
Mechanism of Action and Rationale for Use |
|
|
330 | (1) |
|
|
|
330 | (1) |
|
|
|
330 | (1) |
|
Class IV: Calcium Channel Blockers |
|
|
331 | (1) |
|
Mechanism of Action and Rational for Use |
|
|
331 | (1) |
|
|
|
331 | (1) |
|
|
|
331 | (1) |
|
Speical Concerns in Rehabilitation Patients |
|
|
331 | (1) |
|
|
|
332 | (3) |
|
|
|
332 | (3) |
|
Chapter 24. Treatment of Congestive Heart Failure |
|
|
335 | (13) |
|
Pathophysiology of Congestive Heart Failure |
|
|
336 | (2) |
|
Vicious Cycle of Heart Failure |
|
|
336 | (1) |
|
Congestion in Left and Right Heart Failure |
|
|
337 | (1) |
|
|
|
338 | (1) |
|
|
|
339 | (2) |
|
Effects and Mechanism of Action |
|
|
340 | (1) |
|
|
|
341 | (1) |
|
|
|
341 | (1) |
|
Effects of Mechanism of Action |
|
|
341 | (1) |
|
|
|
342 | (1) |
|
Angiotensin-Converting Enzyme Inhibitors |
|
|
342 | (1) |
|
Effects and Mechanism of Action |
|
|
342 | (1) |
|
|
|
343 | (1) |
|
Other Drugs in Congestive Heart Failure |
|
|
343 | (1) |
|
|
|
343 | (1) |
|
|
|
343 | (1) |
|
|
|
344 | (1) |
|
|
|
344 | (1) |
|
Special Concerns in Rehabilitation Patients |
|
|
344 | (1) |
|
|
|
344 | (4) |
|
|
|
344 | (4) |
|
Chapter 25. Treatment of Coagulation Disorders and Hyperlipidemia |
|
|
348 | (19) |
|
Normal Mechanism of Blood Coagulation |
|
|
349 | (1) |
|
|
|
349 | (1) |
|
|
|
349 | (1) |
|
Drugs Used to Treat Overactive Clotting |
|
|
350 | (7) |
|
|
|
351 | (2) |
|
|
|
353 | (1) |
|
|
|
354 | (2) |
|
Adverse Side Effects of Anticoagulant, Antithrombotic, and Thrombolytic Agents |
|
|
356 | (1) |
|
Treatment of Clotting Deficiencies |
|
|
357 | (1) |
|
|
|
357 | (1) |
|
Deficiencies of Vitamin K-Dependent Clotting Factors |
|
|
357 | (1) |
|
|
|
358 | (1) |
|
Agents Used to Treat Hyperlipidemia |
|
|
358 | (3) |
|
HMG-CoA Reductase Inhibitors |
|
|
359 | (1) |
|
|
|
359 | (1) |
|
Other Lipid-Lowering Agents |
|
|
359 | (1) |
|
Adverse Effects of Antihyperlipidemia Agents |
|
|
359 | (2) |
|
Special Concerns in Rehabilitation Patients |
|
|
361 | (1) |
|
|
|
362 | (5) |
|
|
|
362 | (5) |
| SECTION VI Respiratory and Gastrointestinal Pharmacology |
|
367 | (36) |
|
Chapter 26. Respiratory Drugs |
|
|
369 | (20) |
|
Drugs Used to Treat Minor Respiratory Tract Irritation and Control Respiratory Secretions |
|
|
369 | (4) |
|
|
|
370 | (1) |
|
|
|
370 | (1) |
|
|
|
371 | (1) |
|
Mucolytics and Expectorants |
|
|
372 | (1) |
|
Drugs Used to Maintain Airway Patency in Obstructive Pulmonary Disease |
|
|
373 | (8) |
|
|
|
373 | (3) |
|
|
|
376 | (3) |
|
|
|
379 | (1) |
|
|
|
379 | (1) |
|
|
|
380 | (1) |
|
Treatment of Bronchial Asthma |
|
|
381 | (2) |
|
Pathophysiology of Bronchial Asthma |
|
|
381 | (1) |
|
Long-Term Management of Asthma |
|
|
381 | (1) |
|
Treatment of Reversible Bronchospasm in COPD |
|
|
383 | (1) |
|
Treatment of Respiratory Problems in Cystic Fibrosis |
|
|
383 | (1) |
|
Respiratory Drugs: Special Concerns in Rehabilitation Patients |
|
|
384 | (1) |
|
|
|
385 | (4) |
|
|
|
385 | (4) |
|
Chapter 27. Gastrointestinal Drugs |
|
|
389 | (14) |
|
Drugs Used to Control Gastric Acidity and Secretion |
|
|
389 | (3) |
|
|
|
390 | (1) |
|
|
|
391 | (1) |
|
Other Agents Used to Control and Treat Gastric Ulcers |
|
|
392 | (1) |
|
|
|
393 | (2) |
|
|
|
393 | (1) |
|
|
|
394 | (1) |
|
|
|
395 | (1) |
|
|
|
395 | (2) |
|
|
|
395 | (1) |
|
Specific Agents and Mechanism of Action |
|
|
396 | (1) |
|
|
|
397 | (1) |
|
Miscellaneous Gastrointestinal Drugs |
|
|
397 | (1) |
|
|
|
397 | (1) |
|
|
|
398 | (1) |
|
|
|
398 | (1) |
|
|
|
398 | (1) |
|
Special Concerns in Rehabilitation Patients |
|
|
398 | (1) |
|
|
|
399 | (4) |
|
|
|
399 | (4) |
| SECTION VII Endocrine Pharmacology |
|
403 | (96) |
|
Chapter 28. Introduction to Endocrine Pharmacology |
|
|
405 | (14) |
|
Primary Endocrine Glands and Their Hormones |
|
|
406 | (4) |
|
Hypothalamus and Pituitary Gland |
|
|
406 | (2) |
|
|
|
408 | (1) |
|
|
|
408 | (1) |
|
|
|
409 | (1) |
|
|
|
409 | (1) |
|
|
|
410 | (1) |
|
Endocrine Physiology and Pharmacology |
|
|
410 | (6) |
|
|
|
410 | (1) |
|
Synthesis and Release of Hormones |
|
|
411 | (1) |
|
Feedback Control Mechanisms in Endocrine Function |
|
|
411 | (2) |
|
|
|
413 | (1) |
|
Hormone Effects on the Target Cell |
|
|
413 | (3) |
|
Clinical Use of Endocrine Drugs |
|
|
416 | (3) |
|
Chapter 29. Adrenocorticosteroids |
|
|
419 | (20) |
|
|
|
420 | (1) |
|
|
|
421 | (5) |
|
Role of Glucocorticoids in Normal Function |
|
|
421 | (2) |
|
Mechanism of Action of Glucocorticoids |
|
|
423 | (1) |
|
Physiologic Effects of Glucocorticoids |
|
|
423 | (3) |
|
Therapeutic Glucocorticoid Agents |
|
|
426 | (2) |
|
Clinical Uses of Glucocorticoids |
|
|
428 | (2) |
|
Glucocorticoid Use in Endocrine Conditions |
|
|
428 | (1) |
|
Use in Nonendocrine Conditions |
|
|
429 | (1) |
|
Adverse Effects of Glucocorticoids |
|
|
430 | (1) |
|
Adrenocortial Suppression |
|
|
430 | (1) |
|
Drug-Induced Cushing's Syndrome |
|
|
430 | (1) |
|
Breakdown of Supporting Tissues |
|
|
431 | (1) |
|
|
|
431 | (1) |
|
Drugs That Inhibit Adrenocortical Hormone Biosynthesis |
|
|
431 | (1) |
|
|
|
432 | (1) |
|
Regulation of Mineralocorticoid Secretion |
|
|
432 | (1) |
|
Mechanism of Action and Physiologic Effects of Mineralocorticoids |
|
|
433 | (1) |
|
Therapeutic Use of Mineralocorticoid Drugs |
|
|
434 | (1) |
|
Mineralocorticoid Antagonists |
|
|
434 | (1) |
|
Special Concerns of Adrenal Steroid Use in Rehabilitation Patients |
|
|
434 | (1) |
|
|
|
435 | (4) |
|
|
|
435 | (4) |
|
Chapter 30. Male and Female Hormones |
|
|
439 | (22) |
|
|
|
440 | (2) |
|
Source and Regulation of Androgen Synthesis |
|
|
440 | (1) |
|
Physiologic Effects of Androgens |
|
|
440 | (2) |
|
Pharmacologic Use of Androgens |
|
|
442 | (3) |
|
Clinical Use of Androgens |
|
|
442 | (1) |
|
|
|
443 | (1) |
|
Adverse Effects of Clinical Androgen Use |
|
|
444 | (1) |
|
|
|
444 | (1) |
|
|
|
445 | (3) |
|
|
|
445 | (1) |
|
Effects of Androgens on Athletic Performance |
|
|
446 | (1) |
|
Adverse Effects of Androgen Abuse |
|
|
447 | (1) |
|
Estrogen and Progesterone |
|
|
448 | (3) |
|
Effects of Estrogen and Progesterone on Sexual Maturation |
|
|
448 | (1) |
|
Regulation and Effects of Hormonal Synthesis During the Menstrual Cycle |
|
|
449 | (2) |
|
Female Hormones in Pregnancy and Parturition |
|
|
451 | (1) |
|
Pharmacologic Use of Estrogen and Progesterone |
|
|
451 | (3) |
|
Conditions Treated with Estrogen and Progesterone |
|
|
452 | (1) |
|
|
|
452 | (1) |
|
Adverse Effects of Estrogen and Progesterone |
|
|
453 | (1) |
|
|
|
454 | (1) |
|
|
|
454 | (3) |
|
Types of Contraceptive Preparations |
|
|
454 | (1) |
|
Mechanism of Contraceptive Action |
|
|
455 | (1) |
|
Adverse Effects of Oral Contraceptives |
|
|
456 | (1) |
|
Special Concerns of Sex Hormone Pharmacology in Rehabilitation Patients |
|
|
457 | (1) |
|
|
|
457 | (4) |
|
|
|
457 | (4) |
|
Chapter 31. Thyroid and Parathyroid Drugs: Agents Affecting Bone Mineralization |
|
|
461 | (17) |
|
Function of the Thyroid Gland |
|
|
461 | (3) |
|
Synthesis of Thyroid Hormones |
|
|
462 | (1) |
|
Regulation of Thyroid Hormone Release |
|
|
463 | (1) |
|
Physiologic Effects of Thyroid Hormones |
|
|
464 | (1) |
|
Mechanism of Action of Thyroid Hormones |
|
|
464 | (1) |
|
Treatment of Thyroid Disorders |
|
|
464 | (4) |
|
|
|
465 | (2) |
|
|
|
467 | (1) |
|
Function of the Parathyroid Glands |
|
|
468 | (1) |
|
|
|
468 | (1) |
|
Regulation of Bone Mineral Homeostasis |
|
|
469 | (1) |
|
Pharmacologic Control of the Bone Mineral Homeostasis |
|
|
470 | (4) |
|
|
|
471 | (1) |
|
|
|
472 | (1) |
|
|
|
473 | (1) |
|
|
|
473 | (1) |
|
|
|
474 | (1) |
|
Special Concerns in Rehabilitation Patients |
|
|
474 | (1) |
|
|
|
475 | (3) |
|
Agents Affecting Bone Mineral Metabolism |
|
|
475 | (3) |
|
Chapter 32. Pancreatic Hormones and the Treatment of Diabetes Mellitus |
|
|
478 | (21) |
|
Structure and Function of the Endocrine Pancreas |
|
|
478 | (1) |
|
|
|
479 | (1) |
|
Cellular Mechanism of Insulin Action |
|
|
480 | (1) |
|
|
|
480 | (2) |
|
Control of Insulin and Glucagon Release |
|
|
482 | (1) |
|
|
|
483 | (3) |
|
|
|
484 | (1) |
|
|
|
484 | (1) |
|
Effects and Complications of Diabetes Mellitus |
|
|
485 | (1) |
|
Use of Insulin in Diabetes Mellitus |
|
|
486 | (3) |
|
Therapeutic Effects and Rationale for Use |
|
|
486 | (1) |
|
|
|
486 | (1) |
|
Administration of Insulin |
|
|
487 | (1) |
|
Intensive Insulin Therapy |
|
|
488 | (1) |
|
Adverse Effects of Insulin Therapy |
|
|
489 | (1) |
|
|
|
489 | (2) |
|
Mechanism of Action and Rationale for Use |
|
|
489 | (1) |
|
|
|
490 | (1) |
|
|
|
490 | (1) |
|
Other Drugs Used in the Management of Diabetes Mellitus |
|
|
491 | (1) |
|
|
|
491 | (1) |
|
|
|
491 | (1) |
|
Aldose Reductase Inhibitors |
|
|
491 | (1) |
|
Nonpharmacologic Intervention in Diabetes Mellitus |
|
|
492 | (1) |
|
Dietary Management and Weight Reduction |
|
|
492 | (1) |
|
|
|
492 | (1) |
|
Islet Cell Transplants and Gene Therapy |
|
|
492 | (1) |
|
Significance of Diabetes Mellitus in Rehabilitation |
|
|
492 | (1) |
|
|
|
493 | (6) |
|
|
|
493 | (6) |
| SECTION VIII Chemotherapy of Infectious and Neoplastic Diseases |
|
499 | (98) |
|
Chapter 33. Treatment of Infections I: Antibacterial Drugs |
|
|
501 | (27) |
|
|
|
502 | (2) |
|
Bacterial Structure and Function |
|
|
502 | (1) |
|
Pathogenic Effects of Bacteria |
|
|
502 | (1) |
|
Bacterial Nomenclature and Classification |
|
|
503 | (1) |
|
Treatment of Bacterial Infections: Basic Principles |
|
|
504 | (1) |
|
Spectrum of Antibacterial Activity |
|
|
504 | (1) |
|
Bactericidal Versus Bacteriostatic Activity |
|
|
504 | (1) |
|
Basic Mechanisme of Antibacterial Drugs |
|
|
504 | (4) |
|
Inhibition of Bacterial Cell Wall Synthesis and Function |
|
|
504 | (2) |
|
Inhibition of Bacterial Protein Synthesis |
|
|
506 | (1) |
|
Inhibition of Bacterial DNA/RNA Synthesis and Function |
|
|
506 | (2) |
|
Specific Antibacterial Agents |
|
|
508 | (1) |
|
Antibacterial Drugs That Inhibit Bacterial Cell Wall Synthesis and Function |
|
|
508 | (7) |
|
|
|
508 | (2) |
|
|
|
510 | (1) |
|
Other Agents That Inhibit Bacterial Cell Wall Synthesis |
|
|
511 | (4) |
|
Drugs That Inhibit Bacterial Protein Synthesis |
|
|
515 | (4) |
|
|
|
515 | (2) |
|
|
|
517 | (1) |
|
|
|
517 | (1) |
|
Other Agents That Inhibit Bacterial Protein Synthesis |
|
|
518 | (1) |
|
Drugs That Inhibit Bacterial DNA/RNA Synthesis and Function |
|
|
519 | (3) |
|
|
|
519 | (1) |
|
|
|
520 | (1) |
|
|
|
520 | (1) |
|
|
|
520 | (1) |
|
|
|
520 | (1) |
|
|
|
521 | (1) |
|
|
|
521 | (1) |
|
|
|
521 | (1) |
|
|
|
522 | (1) |
|
Other Antibacterial Drugs |
|
|
522 | (2) |
|
|
|
522 | (1) |
|
|
|
523 | (1) |
|
|
|
523 | (1) |
|
|
|
523 | (1) |
|
|
|
523 | (1) |
|
Clinical Use of Antibacterial Drugs: Relationship to Specific Bacterial Infections |
|
|
524 | (1) |
|
Resistance to Antibacterial Drugs |
|
|
524 | (1) |
|
Special Concerns in Rehabilitation Patients |
|
|
525 | (1) |
|
|
|
526 | (2) |
|
|
|
526 | (2) |
|
Chapter 34. Treatment of Infections II: Antiviral Drugs |
|
|
528 | (19) |
|
Viral Structure and Function |
|
|
528 | (3) |
|
Classification of Viruses |
|
|
528 | (1) |
|
Characteristics of Viruses |
|
|
529 | (1) |
|
|
|
530 | (1) |
|
|
|
531 | (6) |
|
|
|
531 | (2) |
|
|
|
533 | (1) |
|
|
|
533 | (1) |
|
|
|
534 | (1) |
|
|
|
534 | (1) |
|
|
|
535 | (1) |
|
|
|
535 | (1) |
|
|
|
535 | (1) |
|
|
|
536 | (1) |
|
Controlling Viral Infection with Vaccines |
|
|
537 | (1) |
|
|
|
537 | (2) |
|
Synthesis and Cellular Effects of Interferons |
|
|
538 | (1) |
|
Pharmacologic Applications of Interferons |
|
|
539 | (1) |
|
HIV and the Treatment of AIDS |
|
|
539 | (4) |
|
Inhibiting HIV Proliferation in Infected Individuals |
|
|
540 | (2) |
|
Management of Opportunistic Infections |
|
|
542 | (1) |
|
Relevence of Antiviral Chemotherapy in Rehabilitation Patients |
|
|
543 | (1) |
|
|
|
543 | (4) |
|
|
|
543 | (4) |
|
Chapter 35. Treatment of Infections III: Antifungal and Antiparasitic Drugs |
|
|
547 | (17) |
|
|
|
547 | (5) |
|
|
|
548 | (1) |
|
|
|
549 | (1) |
|
|
|
549 | (1) |
|
|
|
550 | (1) |
|
|
|
550 | (1) |
|
|
|
550 | (1) |
|
|
|
551 | (1) |
|
|
|
551 | (1) |
|
|
|
551 | (1) |
|
Other Topical Antifungals |
|
|
552 | (1) |
|
|
|
552 | (1) |
|
|
|
553 | (3) |
|
|
|
553 | (1) |
|
|
|
554 | (1) |
|
|
|
554 | (1) |
|
|
|
554 | (1) |
|
|
|
555 | (1) |
|
|
|
555 | (1) |
|
Drugs Used to Treat Protozoal Infections in the Intestines and Other Tissues |
|
|
556 | (2) |
|
|
|
556 | (1) |
|
|
|
556 | (1) |
|
|
|
557 | (1) |
|
|
|
557 | (1) |
|
|
|
557 | (1) |
|
Other Antiprotozoal Drugs |
|
|
558 | (1) |
|
|
|
558 | (3) |
|
|
|
559 | (1) |
|
|
|
559 | (1) |
|
|
|
560 | (1) |
|
|
|
560 | (1) |
|
|
|
560 | (1) |
|
|
|
560 | (1) |
|
|
|
561 | (1) |
|
|
|
561 | (1) |
|
Significance of Antigungal and Antiparasitic Drugs in Rehabilition |
|
|
561 | (1) |
|
|
|
562 | (2) |
|
|
|
562 | (2) |
|
Chapter 36. Cancer Chemotherapy |
|
|
564 | (21) |
|
|
|
565 | (2) |
|
|
|
565 | (1) |
|
Cell-Cycle-Specific Versus Cell-Cycle-Nonspecific Drugs |
|
|
565 | (1) |
|
Concepts of Growth Fraction and Total Cell Kill |
|
|
566 | (1) |
|
Incidence of Adverse Effects |
|
|
566 | (1) |
|
|
|
567 | (8) |
|
|
|
567 | (1) |
|
|
|
568 | (3) |
|
|
|
571 | (1) |
|
|
|
571 | (4) |
|
|
|
575 | (1) |
|
|
|
575 | (1) |
|
|
|
575 | (2) |
|
|
|
576 | (1) |
|
|
|
577 | (1) |
|
Use of Anticancer Drugs with Other Treatments |
|
|
577 | (1) |
|
Success of Anticancer Drugs |
|
|
578 | (1) |
|
Resistance to Cancer Chemotherapy Drugs |
|
|
579 | (1) |
|
|
|
580 | (1) |
|
Implications of Cancer Chemotheraphy in Rehabilitation Patients |
|
|
581 | (4) |
|
|
|
581 | (1) |
|
|
|
581 | (4) |
|
Chapter 37. Immunosuppressive Agents |
|
|
585 | (12) |
|
Overview of the Immune Response |
|
|
586 | (1) |
|
Pharmacologic Modification of the Immune Response |
|
|
587 | (2) |
|
Specific Immunosuppressive Agents |
|
|
589 | (4) |
|
|
|
589 | (1) |
|
|
|
589 | (1) |
|
|
|
590 | (1) |
|
|
|
590 | (1) |
|
|
|
591 | (1) |
|
|
|
592 | (1) |
|
|
|
592 | (1) |
|
Other Methods of Immunosuppression |
|
|
593 | (1) |
|
Significance of Immuniosuppressive Agents in Rehabilitation |
|
|
593 | (1) |
|
|
|
594 | (3) |
|
|
|
594 | (3) |
| Appendix A: Drugs Administered by Iontophoresis and Phonophoresis |
|
597 | (3) |
| Appendix B: Potential Interactions Between Physical Agents and Therapeutic Drugs |
|
600 | (3) |
| Appendix C: Use of the Physicans' Desk Reference |
|
603 | (2) |
| Appendix D: Drugs of Abuse |
|
605 | (3) |
| Appendix E: Common Drug Suffixes |
|
608 | (2) |
| Glossary |
|
610 | (9) |
| Index |
|
619 | |
Shopping Cart
